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Background: TNF receptors (TNFR1 and TNFR2) and Fas belong to the system of apoptosis-sig-
nalling receptor molecules and may play a role in the pathogenesis of interstitial lung disease.
Patients with cryptogenic organizing pneumonia (COP) usually respond well to corticosteroids,
in contrast to those with idiopathic pulmonary fibrosis (IPF). This may be due to the different
pathogenesis.
Methods: The expression of TNFR1, TNFR2 and Fas on bronchoalveolar lavage (BAL) macro-
phages and lymphocytes was analysed in 9 patients with COP, 10 with IPF and 12 controls.
The production of soluble TNFR1, 2 and TNF-a by alveolar macrophages was measured by ELISA.
Results: TNFR1 and Fas expression on alveolar macrophages was significantly higher in COP than
in controls and IPF. The expression of TNFR2 on alveolar macrophages was also increased in COP
compared to controls. Theexpression of TNFR2andFas on lymphocyteswas significantly higher in
COP than in IPF and controls. In addition, the expression of TNFR1, TNFR2 and Fas on BAL cells
correlated positively with BAL lymphocytes (p < 0.05 or p < 0.01). The production of sTNFR1
and 2 and TNF-a by macrophages in vitro was significantly increased in patients with COP
compared to IPF and controls, spontaneously or with LPS stimulation (p < 0.05 or
p < 0.01).There was a positive correlation between the spontaneous production of sTNFR2 and
TNF-a (rZ 0.494, p < 0.01).nizing pneumonia; BOOP, bronchiolitis obliterans organizing pneumonia; HP, hypersensitivity pneu-
osis; sTNFR, soluble tumor necrosis factor receptor; TNF, tumor necrosis factor; TNFR, tumor necrosis
pneumonia.
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Tumor necrosis factor receptors in cryptogenic organizing pneumonia 293Conclusions: This study showed an increased expression of TNF receptors and Fas on BAL cells in
COP that may be indicative of the local inflammatory activity in the lung. The biologic effects of
this expression needs further investigation.
ª 2010 Elsevier Ltd. All rights reserved.Table 1 Demographics of the study population.
COP IPF controls
n, female:male 9, 4:5 10, 1:9 12, 5:7
Age, yr 61  4 70  3# 53  5
nonsmokers, n 9 6 6
current smokers, n 0 0 2
ex-smokers, n 1 4 4
VC, l 2.7  0.2 2.2  0.1 3.0  0.1
VC, %pred 76  8 64  4## 80  3
TLC, l 4.1  0.2 3.7  0.2## 4.8  0.2
TLC, %pred 76  7 58  5## 86  4
FEV1/VC, % 71  3 82  3 75  3
PaO2, mmHg 71  3 72  4 81  3
AaDO2, mmHg 34  4* 28  4 19  3
Data are expressed as mean  SEM. Definition of abbreviations:
IPF Z idiopathic pulmonary fibrosis; COP Z cryptogenic orga-
nizing pneumonia; VC Z vital capacity; TLC Z total lung
capacity; FEV1 Z forced expiratory volume in 1 s.
*p < 0.05 (COP vs controls).
#p < 0.05.
##p < 0.01 (IPF vs controls).Introduction
Cryptogenicorganizingpneumonia (COP),alsocalled idiopathic
bronchiolitis obliterans organizing pneumonia (BOOP), is an
inflammatory lung disease rather than a fibrosing process as
idiopathic pulmonary fibrosis (IPF).1 Clinically, patients with
COP usually achieve a good response to corticosteroid therapy
and subsequently have a much better prognosis compared to
IPF which may be due to the different pathogenesis.2
Tumor necrosis factor (TNF-a) is a mononuclear phag-
ocyteederived cytokine, which has been increasingly recog-
nized for its diverse effects on numerous inflammatory and
immunologic responses.3 TNF-a exerts its function by binding to
its cognate receptors TNFR1 (p55/60, CD120a) and TNFR2 (p75/
80, CD120b). These receptors can exist asmembrane-associated
or soluble proteins.3,4 The soluble receptors possess TNF-
neutralizing ability. TNFR1 shares homology with Fas and
contains a death domain in the cytoplasmic tail capable of
transducing a death signal. The role of TNFR2 during TNF medi-
ated signal transduction is indirect that it aids the recruitmentof
TNF to the cell membrane and passes the signal to TNFR1 or
regulates the amount of TNF which is accessible to TNFR1.3e5
Elevated levels of TNF-a and TNFRs have been implicated
in the pathogenesis of granulomatous and inflammatory lung
diseases.6e10 The use of a recombinant soluble TNF receptor
that impairs binding of TNF to cellular TNF receptors resulted
in a marked reduction of the pulmonary inflammation and
fibrosis in the bleomycin-induced animalmodel.11 The role of
TNF in COP is still not clear. TNF-a mRNA was shown to be
expressed in the lungs of reovirus 1/L induced intraluminal
fibrosis in CBA/J mice, an animal model of COP.12 BOOP
lesions in children with Crohn’s disease responded to treat-
ment with infliximab, a monoclonal antibody to TNF-a.13
Based on this background and the fact that COP is a Th1
cytokine driven inflammatory disease,12,14 we hypothesize
that the expression of TNF-a and its receptors is increased in
COP in comparison with IPF, a chronic fibroproliferative
disease associated with a Th2 mediated response. To test this
hypothesis, we evaluated the expression ofmembrane-bound
TNFR1, TNFR2, and Fas on alveolar cells in patients with COP,
in comparisonwithpatientswith IPF andcontrol subjects. The
potential correlations between the expression of TNFRs on
BAL cells and the release of soluble TNFRs and TNF-a from
alveolar macrophages in vitro were also explored.
Methods
Patients
Nine consecutive patients with COP, 10 with IPF, and 12
control subjects were investigated (Table 1). No patient
was receiving treatment with corticosteroids and/or
immunosuppressants at the time of BAL. Written informed
consent was obtained according to institutional guidelines.Nine COP patients fulfilled the following diagnostic
criteria: (1) acute or subacute onset of an illnesswith variable
degrees of cough and dyspnea, chills, intermittent fever, and
myalgia, (2) radiologic features of the areas of airspace
consolidation with a subpleural or peribronchial distribution,
(3) pulmonary function abnormalities suggesting characteris-
tics of interstitial lung disease, (4) no evidence of infection or
tumor, or other known causes of interstitial lung disease, such
as connective tissue disease, hypersensitivity pneumonitis
(HP), drug toxicities, radiation induced lung injury, (5) lung
biopsy showing patchy distribution of intraluminal organizing
fibrosis in distal airspaces, with preservation of lung archi-
tecture. Seven of the patients underwent a transbronchial
lung biopsy and two had a surgical biopsy with histological
evidence of organizing pneumonia.
Ten IPF patients were diagnosed according to the ATS/
ERS criteria.15 Three of them had a surgical biopsy with
histological evidence of usual interstitial pneumonia (UIP).
Twelve patients underwent diagnostic bronchoscopy and
showed no evidence of interstitial lung disease. They had
normal BAL cytology, and served as controls.
Bronchoalveolar lavage Procedure
BAL was performed during fiberoptic bronchoscopy accord-
ing to established guidelines. Sterile isotonic saline solution
was instilled into the right middle or left lingular lobe in
20 mL aliquots to a total volume of 100e200 mL, with
immediate aspiration by gentle suction after each aliquot. A
volume of greater than 50% was retrieved. The BAL cell
differentials of the four study groups are shown in Table 2.
Table 2 Bronchoalveolar lavage cell differentials.
COP IPF controls
Total cells,
104/mL
19.5  6.4 11.0  2.0 17.6  3.2
Macrophages, % 53.3  6.3** 77.3  3.1* 90.9  0.9
Lymphocytes, % 29.6  4.6***,# 9.9  1.9 7.1  0.7
Neutrophils, % 13.9  4.6* 10.8  3.1* 1.7  0.4
Eosinophils, % 2.3  0.7** 2.4  0.6*** 0.1  0.1
Mast cell, % 1.2  0.6 0.2  0.1 0.003  0.002
Plasma cell, % 0.07  0.06 0 0
Data are expressed as mean  SEM.
*p < 0.05, **P < 0.01, ***p < 0.001 (COP or IPF vs controls).
#p < 0.05 (COP vs IPF).
Figure 1 Expression of TNFR1, 2 and Fas on BAL alveolar
macrophages (AM) in COP, IPF and controls.
)
: p < 0.05,
))
: p < 0.01 (COP vs controls); ##: p < 0.01 (COP vs IPF).
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Immunocytochemistry was used to investigate the expres-
sion of Fas (Upstate Biotechnology Incorporated, New York,
USA), TNFR1 (Bender MedSystems, Vienna, Austria), and
TNFR2 (Serotec Ltd, Oxford, Great Britain) on BAL cells.
The peroxidase- antiperoxidase method was applied as
previously described.16 To evaluate the percentage of
antibody positive cells, 300 macrophages or lymphocytes
were counted under a light microscope. The proportion of
positive cells was expressed as % of total macrophages or %
of total lymphocytes. All analyses were performed in
a blinded fashion by two investigators. The interobserver
correlation was good. The Spearman’s r value for the
correlation between the two counts was 0.92 (p < 0.01).
Culture of alveolar macrophages
Alveolar macrophage cultures were performed in 9 patients
with COP, 10 patients with IPF, and 12 controls, as previously
described.17 The alveolar macrophages from BAL were
incubated for 24 h with 1 mL RPMI 1640 medium alone, or
RPMI 1640 medium with 100 ng/mL lipopolysaccharide (LPS,
Sigma). The culture supernatants were centrifuged and
stored at e 80 C until analysed.
ELISA assay for cytokines
The concentration of TNF-a and sTNFR1 and 2 in culture
supernatants was quantified using commercially available
human enzyme-linked immunosorbent assay (ELISA) kits
(Endogen, Woburn, MA, USA, and HyCult Biotechnology,
Uden, Holland) with a sensitivity of <5 pg/mL and 25 pg/mL
respectively. The concentrations of above-measured
sTNFRs and TNF-a were expressed as picogram per milliliter
per 106 macrophages, in order to correct for the proportion
of macrophages.
Statistical analysis
Values are expressed as mean  SEM. To compare the
three study populations COP, IPF, and controls, the data
were analysed using KruskaleWallis one-way analysis of
variance on ranks. Two groups were compared using
Student t-test for parametric data. The correlation ofdifferent parameters was analysed by Spearman rank. The
correlations between TNF or TNFRs and the age of patients
were analysed using linear regression analysis. A level of
p < 0.05 was accepted as statistically significant.
Results
Expression of TNFR1, 2 and Fas on BAL cells in the
patients with COP, IPF and controls
As shown in Fig. 1, TNFR1 and Fas expression on alveolar
macrophages was significantly higher in COP than in controls
and IPF. The expression of TNFR2 on alveolar macrophages
was increased in COP compared to in controls. The expres-
sion of TNFR2 and Fas on lymphocytes was also significantly
higher in COP than in controls and in IPF (Fig. 2). TNFR1 was
not expressed on lymphocytes. The expression of TNFR1,
TNFR2 andFas onalveolarmacrophages correlatedpositively
with the percentage of lymphocytes of BAL (r Z 0.517,
p < 0.01; r Z 0.537, p < 0.01; or r Z 0.574, p < 0.001,
respectively). The expression of TNFR2 and Fas on BAL
lymphocytes also correlated positively with the percentage
of lymphocytes of BAL (r Z 0.382, p < 0.05; r Z 0.560,
p < 0.001 respectively). In addition, there were significant
correlations between the expression of TNFR1, TNFR2 and
Fas by BAL macrophages.
Production of sTNFR1, 2 and TNF-a by BAL alveolar
macrophages in the patients with COP, IPF and
controls
The spontaneous production of sTNFR1, 2 and TNF-a by
macrophages in vitro was significantly increased in patients
with COP compared with IPF and controls (p < 0.05 or
p < 0.01 respectively, Fig. 3). After LPS stimulation, the
production of sTNFR1 and TNF-a by macrophages was also
significantly increased in patients with COP compared with
IPF and controls (p < 0.05 or p < 0.01 respectively,
Table 3); the production of sTNFR2 showed only a tendency
to be increased in COP. As shown in Fig. 4, there was
a positive correlation between the spontaneous production
of sTNFR2 and TNF-a (r Z 0.494, p < 0.01).
Table 3 The LPS stimulated production of sTNFR1, 2 and
TNF-a by alveolar macrophages in COP, IPF and controls.
COP IPF controls
sTNFR1, pg/mL
per 106 AMs
378  63**,# 230  18 190  20
sTNFR2, pg/mL
per 106 AMs
1054  195 721  164 492  126
TNF-a, pg/mL
per 106 AMs
22841  7661* 10780  2280 4458  1212
Data were presented as mean  SEM.
*: p< 0.05, **: p< 0.01 (COP vs controls); #: p< 0.05 (COP vs IPF).
Figure 2 Expression of TNFR1, 2 and Fas on BAL lymphocytes
in COP, IPF and controls.
))
: p < 0.01 (COP vs controls);
#: p < 0.05 (COP vs IPF).
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The present study showed that the expression of TNFR1 and
Fas on BAL macrophages and lymphocytes is increased in
patients with COP. TNFR2 was not expressed by BAL
lymphocytes but was also increased on BAL macrophages in
COP compared to controls. In addition, the expression of
TNFR1, 2 and Fas correlated positively with the BAL
lymphocyte percentage. In COP patients, the production of
sTNFR1, 2 and TNF-a by alveolar macrophages in vitro was
also elevated, and there was a positive correlation between
the spontaneous production of sTNFR2 and TNF-a.
COP is characterized by the presence of granulation
tissue in the bronchiolar lumen, alveolar ducts and alveoli,
associated with a variable degree of interstitial and
airspace infiltration by mononuclear cells and foamy
macrophages.1 The new fibromyxoid connective tissue
formation can be fully reversed with corticosteroid therapy
in COP, in marked contrast to the fibrotic changes in IPF.2 AFigure 3 Spontaneous production of sTNFR1, 2 and TNF-a by
alveolar macrophages (AM) in patients with COP, IPF and
controls.
)
: p < 0.05,
))
: p < 0.01 (COP vs controls);
#: p < 0.05, ##: p < 0.01 (COP vs IPF).complex immune reaction plays a role in the pathogenesis
of COP. A body of evidence suggests that COP is predomi-
nantly mediated by Th1 cytokines,12,14 while IPF shifts to
the Th2 immune response. The cytokine profile of BAL in
COP is characterized by increased monocyte chemotactic
protein-1, IL-10, IL-12 and IL-18 levels with respect to IPF/
UIP and controls, consistent with a marked degree of
macrophage and lymphocyte activation with an expansion
of the Th1 response in COP.14 Our results are in agreement
with this previous study by showing that alveolar macro-
phages and lymphocytes are activated in terms of increased
expression of membrane TNFR receptors and Fas.
With corticosteroid therapy, the disappearance of myo-
fibroblasts and fibroblasts in fibrosis may occur through
apoptosis.18 Apoptotic activity has been shown to be
increased in the newly formed connective tissue in orga-
nizing pneumonia.19 The FaseFas ligand pathway is impli-
cated in the system of apoptosis-signalling receptor
molecules. A previous report showed that the soluble form
of Fas is elevated in the BAL fluid of patients with COP in
comparison to IPF or controls.20 The present study revealed
that the Fas membrane expression on alveolar macrophages
and BAL lymphocytes is also enhanced in COP in comparison
to IPF or controls.Figure 4 Correlation between the production of sTNFR2 and
TNF-a by alveolar macrophages (AM) in the patients with COP,
IPF and controls.
296 Q. Ye et al.TNF-a, as a multipotent cytokine, bridges inflammation,
reparative responses, fibrosis and may be involved in
extracellular matrix remodeling.21,22 Elevated levels of TNF
have been implicated in the pathogenesis of a number of
inflammatory disease states. TNF-a is thought to be inte-
grally involved in the granulomatous inflammation, and
anti-TNF-a therapy has shown efficacy in sarcoidosis.23
Moreover, mutations in receptors for TNF and its related
ligands play a role in autoimmune disorders.24 Anti-TNF
therapies are capable of ameliorating autoimmune disor-
ders such as rheumatoid arthritis.25 Similar to the current
study on COP, our previous studies demonstrated an upre-
gulated expression of TNFR1 and 2 on the surface of BAL
macrophages and lymphocytes in sarcoidosis26 and HP6
which are also considered to be Th1 mediated diseases. The
increased TNFR expression provides the sites for TNF-
a ligation and may enhance the TNF-a mediated immune
reactions in the disease process.
Healthy individuals show a low concentration of soluble
TNFRs in peripheral blood,27 whereas elevated levels of
soluble TNFRs in biological fluids are found in a variety of
TNF-a involved inflammatory disorders including sarcoidosis
and HP.6e10 The TNF-a action can be attenuated by natu-
rally occurring soluble TNFRs.28 Nevertheless, the endoge-
nous soluble TNFRs are not always sufficient to neutralize
the TNF-a cytotoxicity.8,28 Administration of recombinant
sTNFRs may minimize the pathological process caused by
exaggerated TNF-a.11,29
A limitation of this study is that the age was different
between the groups. It is unlikely that this has an effect on
the measurements. Using linear regression analysis, no
correlations were found between TNF or TNFRs and age.
In summary, we demonstrate here enhanced expression
of TNF receptors and Fas on BAL cells in COP that may
indicate the local inflammatory activity of the lungs. The
biologic effects of TNF and its receptors in the pathogenesis
of COP need to be further investigated.Acknowledgements
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